Healthequity is a leading provider of health savings accounts and other consumer-directed benefits, facilitating individuals and employers in managing healthcare expenses. The company offers a robust platform that integrates various services, including healthcare spending accounts, wellness services, and insurance products, aimed at empowering consumers to make informed healthcare decisions. By promoting cost-saving strategies and enhancing access to critical healthcare resources, Healthequity plays a vital role in the healthcare ecosystem, making it easier for users to navigate their financial responsibilities associated with medical care. Read More
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Based on fundamental and technical analysis of NASDAQ:HQY we ask: Why HEALTHEQUITY INC (NASDAQ:HQY) Is a Standout High-Growth Stock in a Consolidation Phase.
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of HealthEquity, Inc. (NASDAQ: HQY) resulting from allegations that HealthEquity may have issued materially misleading business information to the investing public.
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
HealthEquity's Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.
CFO James Lucania said on the earnings call that fraud prevention efforts are ongoing, and service expenses are expected to remain elevated through the first half of fiscal 2026.
